Previous 10 | Next 10 |
2024-01-08 08:46:55 ET Aclarion ( ACON ) +111% Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan. Harpoon Therapeutics ( HARP ) +110% stock surges as Merck reportedly in talks for $700M acquisition. Ambrx Biopharma ( ...
CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 20, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”)...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 14, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”)...
2023-11-29 13:41:04 ET Addex Therapeutics Ltd. (ADXN) Q3 2023 Earnings Conference Call November 29, 2023, 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Robert Lutjens - Head of Discovery-Biology Mikhail Kalinichev - Head of Translational Sci...
Addex Therapeutics Ltd (ADXN) is expected to report $-4 for Q3 2023 Eco Wave Power Global AB (publ) (WAVE) is expected to report for quarter end 2023-09-30 AmeraMex International, Inc. (AMMX) is expected to report for Q3 2023 iClick Interactive Asia Group Limited (ICLK) is expected to...
2023-11-29 01:31:59 ET More on Addex Therapeutics Historical earnings data for Addex Therapeutics Financial information for Addex Therapeutics For further details see: Addex Therapeutics GAAP EPS of -CHF0.03, income of CHF0.33M
ADX71149 Phase 2 epilepsy clinical study completes recruitment of patients, with top line results expected in Q2 2024 mGlu2 NAM cognition program receives a €4 million Eurostars grant CHF 4.8M ($5.2M) of cash and cash equivalents at September 30, 2023 Ad Hoc A...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 28, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that an Extraor...
Verisante Technology (VRSEF) is expected to report for Q1 2024 American Biltrite Inc. (ABLT) is expected to report for quarter end 2023-09-30 Horiba Ltd (HRIBF) is expected to report for Q3 2023 China Shenhua Energy Co Ltd ADR (CSUAY) is expected to report for Q3 2023 Denso Corpor...
News, Short Squeeze, Breakout and More Instantly...
Addex Therapeutics Ltd Company Name:
ADXN Stock Symbol:
NASDAQ Market:
Addex Therapeutics Ltd Website:
2024-07-19 15:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological...
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of T...